Pharmacokinetics of Voriconazole in Adult ECMO Patients

Launched by UNIVERSITY HOSPITALS, LEICESTER · Apr 27, 2021

Keywords

ClinConnect Summary

This clinical trial is studying how the medication voriconazole works in adult patients who are on ECMO, a form of life support used in serious cases. Voriconazole is an antifungal medication that can help treat infections caused by fungi, particularly in patients who are critically ill with conditions like influenza, COVID-19, or serious fungal infections. The goal of the study is to determine the best dose of voriconazole for these patients, ensuring it is both effective and safe.

To participate in this study, individuals must be adults aged 18 and older who are currently in the ICU and receiving ECMO support. They also need to have tested positive for influenza or COVID-19 and have signs of a fungal infection. Participants will be monitored closely during the trial to understand how their bodies process the medication. This research is important because it aims to improve treatment for patients facing severe respiratory infections complicated by fungal infections, ultimately helping them recover better.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Adults aged ≥18 years
• • 2. Admitted to ICU on ECMO support
• • 3. Positive influenza or SARS-CoV-2 PCR from nasal, throat swab, BAL or other respiratory specimen.
• • 4. Positive invasive aspergillosis infection (positive Aspergillus species culture from respiratory specimen or positive serum galactomannan) or strong clinical suspicion of invasive aspergillosis infection based on symptoms, CT, CXR.
• Exclusion Criteria:
• • 1. No participants \< 18 years of age
• • 2. Not requiring ECMO support
• • 3. No positive influenza or SARS-CoV-2 results
• • 4. Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the trial, or may influence the result of the trial, or the participant's ability to participate in the trial.